I was diagnosed with PCOS in my twenties and told it was mainly a fertility issue. Do I need to follow up now?

This study suggests yes — the cardiovascular risk in PMOS is not fully explained by the metabolic conditions typically monitored at diagnosis. If you haven't had a formal cardiovascular risk review since your original PCOS diagnosis — blood pressure, fasting lipids, fasting glucose or HbA1c, waist circumference, and a family history discussion — that conversation is worth having with your GP, particularly as you approach or enter perimenopause. The study doesn't yet tell us which interventions reduce the risk, but establishing your baseline is a reasonable and proportionate step.

PMOS raises cardiovascular risk four-fold — even when weight is controlled

Q: What is atherosclerotic cardiovascular disease and why does PMOS affect it?

Atherosclerotic cardiovascular disease refers to conditions caused by fatty plaque build-up inside arterial walls — the primary mechanism behind most heart attacks and a significant proportion of strokes. The PMOS-related risk appears to involve chronic low-grade inflammation, endothelial dysfunction driven by androgen excess, and dyslipidaemia patterns that don't always register in standard lipid panels. These processes appear to create an independent atherogenic environment that persists even when weight, blood pressure, and cholesterol are within normal range — which is why the four-fold risk signal survived statistical adjustment for those factors.

What just happened

A large US retrospective cohort study published this week in The Lancet Obstetrics, Gynaecology, & Women’s Health has put a specific number on something Australian GPs have been circling for years: the independent cardiovascular risk carried by polycystic ovary syndrome — now being recategorised as polyendocrine metabolic ovarian syndrome (PMOS).

The study analysed 2.4 million US women over 22 years, including 413,000 with PMOS diagnosed between ages 18 and 50. Women with PMOS faced a four-fold higher risk of atherosclerotic cardiovascular disease events — heart attacks, strokes, and conditions driven by arterial plaque build-up — compared to women without the condition.

The finding that shifts this from interesting to significant: the risk held up after statistical adjustment for obesity, hypertension, elevated cholesterol, and type 2 diabetes. These are the comorbidities that are supposed to explain PMOS-associated cardiovascular risk in the standard clinical narrative. Strip them out, and the risk remains. Something else is driving it.

The both-and

What this overturns

The dominant management frame for PCOS/PMOS for the last three decades has been reproductive: manage the ovarian features, support fertility if that is the patient’s priority, and discharge into routine adult care once that reproductive stage closes.

This study does not overturn what we know about metabolic management in PMOS — treating insulin resistance, managing hyperandrogenism, and monitoring for type 2 diabetes remain important. What it questions is the assumption that doing those things adequately reduces the cardiovascular risk to background level. The data suggest it does not. The independent mechanism — chronic low-grade inflammation, endothelial dysfunction driven by androgen excess, and dyslipidaemia patterns that do not always register in standard lipid panels — adds a burden that is not fully captured by the conventional risk factors we screen.

What the study cannot tell us

The dataset is insurance-derived from the United States, which limits how directly the numbers translate to Australian women. PMOS diagnostic rates, metabolic management patterns, and healthcare access differ across health systems. Whether the four-fold figure holds in an Australian cohort is an open empirical question.

More importantly: the study cannot tell us whether the cardiovascular risk is modifiable. Does early and adequate lifestyle intervention in the PMOS years reduce the late cardiovascular burden? Does long-term metformin change the trajectory? Does treating hyperandrogenism to target matter for arterial health? These are unanswered. The study establishes the risk exists; it does not tell us which clinical actions move it.

The perimenopause intersection

Melbourne-based Associate Professor Magdalena Simonis told RACGP NewsGP that clinicians need to “identify and manage PMOS from as early as possible and not take a ‘set and forget’ approach.” The ‘set and forget’ problem is real. An estimated 1 in 8 Australian women have PMOS. Many were diagnosed in their twenties with a reproductive focus, received no formal cardiovascular monitoring plan, and have had limited follow-up since their fertility priorities changed.

They are now in their forties — entering perimenopause. Oestrogen loss at this stage removes a degree of cardiovascular protection at precisely the moment when years of PMOS-related atherogenesis may have had time to compound. The combination is not a theoretical concern. It is a plausible mechanism that this dataset has now given statistical weight to.

My two cents

I see a version of this in clinical practice. A woman in her late forties mentions her PCOS diagnosis from twenty years ago, but it has not been part of a medical conversation since her children were born. Her periods have settled. She is not thinking about fertility. And no one has told her that her cardiovascular risk baseline may be significantly different from a woman without PMOS — regardless of her weight or her cholesterol reading.

The practical ask is not complicated. If you carry a PCOS or PMOS diagnosis and you have not had a cardiovascular risk conversation with your GP since: that conversation now has a specific, data-grounded reason to happen. Bring the diagnosis into the room. Ask whether your risk factors have been formally reviewed in light of it. A blood pressure measurement, fasting lipids, blood glucose or HbA1c, and a family history discussion are the starting point.

The study does not tell us yet whether early action changes the long-term outcome. But it tells us clearly that the risk is there, it is specific to the condition rather than just its metabolic companions, and it does not disappear at menopause.

Verdict: yes — large Lancet dataset, statistically independent of the usual risk factors, directly relevant to the estimated 1 in 8 Australian women with PMOS approaching or in perimenopause.

Sources cited

PMOS linked to four-fold heart disease risk rise. RACGP NewsGP, 24 July 2026. https://www1.racgp.org.au/newsgp/clinical/pmos-linked-to-four-fold-heart-disease-risk-rise
The Lancet Obstetrics, Gynaecology, & Women’s Health. https://www.thelancet.com